neuroendocrine pulmonary tumor with local invasion and poor response to radiochemotherapy; however during therapy she was diagnosed with bilateral ovarian tumors and ascites which significantly impeded the respiratory function. In order to exclude the presence of a synchronous ovarian cancer and to improve the respiratory function, a total hysterectomy with bilateral adnexectomy was performed; meanwhile 5.5 l of ascites were removed. The histopathological studies demonstrated the metastatic origin of the lesion and enabled the oncologist to administer a second line cytotoxic therapy. However, the patient died of disease after the first cycle of chemotherapy.

**Conclusion** Although very rare conditions, Krukenberg tumors from ovarian cancer should be suspected whenever an association of confirmed pulmonary malignancy and incidental suspect ovarian tumors are found.

**Introduction/Background** Ovarian granulosa cell tumors represent a particular subset of ovarian tumors characterized through a low rate of multiplication of the tumoral cells and a low risk of developing distant metastases. However, in isolated cases recurrences might develop.

**Methodology** The current paper presents the cases of two patients diagnosed with mesosigmoidian metastases from ovarian granulosa cell tumors.

**Results** The first case was investigated for diffuse abdominal pain after an incidental abdominal trauma while the second case was investigated for subocclusive syndrome. In the first case the preoperative suspicion of diagnostic was of a retroperitoneal hematoma while in the other case the preoperative suspicion of diagnostic was of peritoneal carcinomatosis. Intraoperatively in the first case a large ruptured recurrence with perilesional hematoma was found while in the second case a recurrent tumor at the level of the mesosigmoidian area, in close contact with the sigmooidal lumen was found. In both cases a rectosigmoidian resection was performed, the histopathological studies demonstrating the presence of mesosigmoidian recurrences.

**Conclusion** Although ovarian granulosa cell tumors usually exhibit a good prognostic and a low rate of recurrence, relapsed tumors with atypical locations might be found. In such cases different visceral resections might be needed in order to control the disease.

---

**Abstract**

**2022-RA-455-ESGO**

**TYPICAL RECURRENCES OF OVARIAN GRANULOSA CELL TUMOR RECURRENCE**

Nicole Bacalbasa, Irina Balescu. Carol Davila University, Bucuresti, Romania

**Introduction/Background** Cytoreductive surgery for advanced ovarian cancer commonly involves bowel resection. Although gynaecological oncologists in the UK are trained in bowel surgery, there exists national variations in the degree to which these specialists perform bowel surgery independently. A recent joint policy statement from the British Gynaecological Cancer Society (BGCS) emphasises the need for formalised colorectal support for cytoreductive surgery.

**Methodology** An anonymous, online survey was emailed to members of the BGCS to assess the current status of multidisciplinary working between gynaecological oncology and colorectal/general surgical teams in the UK. The survey explored access to colorectal surgeons in the pre and peri operative periods and the role of colorectal/general surgical support in common bowel procedures performed during cytoreductive surgery, alongside their input with surgical complications and post-operative management.

**Results** 46 members responded (8.2% response rate). There was a large variety in the involvement of colorectal and general surgical teams in pre-operative planning. Despite nearly all respondents working in tertiary care centres, 13% of respondents had no formalised agreement for intraoperative support. 72.1% of respondents independently performed rectal peritoneal stripping and 60.5% of respondents independently performed small bowel resection. This reduced to only 27.9% for right hemicolectomy with primary anastomosis and 16.3% for left hemicolectomy with primary anastomosis. Respondents often involved colorectal support for post-operative complications.

---

**2022-RA-456-ESGO**

**GYNAE-ONCOLOGY SURGEONS’ PREPAREDNESS TO UNDERTAKE COLORECTAL PROCEDURES DURING CYTOREDUCTIVE SURGERY FOR OVARIAN CANCER: A CROSS SECTIONAL SURVEY**

1Daniel Huddart, 2Savithri Rajkumar, 3Gautam Mehra, 4Rahul Nath, 5Ahmad Sayasneh, 6Women’s Health, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 7King’s College London, London, UK

**Introduction/Background** Cytoreductive surgery for advanced ovarian cancer commonly involves bowel resection. Although gynaecological oncologists in the UK are trained in bowel surgery, there exists national variations in the degree to which these specialists perform bowel surgery independently. A recent joint policy statement from the British Gynaecological Cancer Society (BGCS) emphasises the need for formalised colorectal support for cytoreductive surgery.

**Methodology** An anonymous, online survey was emailed to members of the BGCS to assess the current status of multidisciplinary working between gynaecological oncology and colorectal/general surgical teams in the UK. The survey explored access to colorectal surgeons in the pre and peri operative periods and the role of colorectal/general surgical support in common bowel procedures performed during cytoreductive surgery, alongside their input with surgical complications and post-operative management.

**Results** 46 members responded (8.2% response rate). There was a large variety in the involvement of colorectal and general surgical teams in pre-operative planning. Despite nearly all respondents working in tertiary care centres, 13% of respondents had no formalised agreement for intraoperative support. 72.1% of respondents independently performed rectal peritoneal stripping and 60.5% of respondents independently performed small bowel resection. This reduced to only 27.9% for right hemicolectomy with primary anastomosis and 16.3% for left hemicolectomy with primary anastomosis. Respondents often involved colorectal support for post-operative complications.

**Conclusion** Overall, the degree to which gynaecological oncologists independently perform bowel procedures varies within the UK. The majority involve colorectal or general surgical teams in such procedures. Surgical team involvement is more common for large bowel procedures compared to small bowel.
and for left colon compared to right colon procedures. Nevertheless, 16.3% of respondents were able to independently perform all bowel procedures surveyed. Future research should examine factors such as training and experience within these groups to address this disparity.

**Abstracts**

**2022-RA-459-ESGO**

**UPLIFT (ENGOT-OV67/GOG-3048) A REGISTRATIONAL TRIAL OF UPFITAMAB RILSDOTIN (XMT-1536; UPRI), A NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) IN PLATINUM-RESISTANT OVARIAN CANCER**

1Nicole Concin, 2Bradley J Monk, 3Mansoor Raza Mirza, 4Robert L Coleman, 5Isabelle Ray-Coquard, 6Bhavana Pothuri, 7Jean-Francois Baurain, 8J Alejandro Perez-Fidalgo, 9David Cibuła, 10Antonella Saverse, 11Susana Banerjee, 12Radek Madry, 13Christian Marth, 14Emily Putri, 15Jamie Baret, 16Leslie DeMars, 17Debra Richardson, 18Evangelische Kliniken Essen-Mitte, Essen, Germany; 19University of Arizona College of Medicine, Tucson, AZ; 20Righospitalet – University Hospital Copenhagen, Copenhagen, Denmark; 21US Oncology, The Woodlands, TX; 22Leon Berard Center, Lyon, France; 23NYU Langone Medical Center, New York, NY; 24Saint Luc University Hospital, Brussels, Belgium; 25University Clinical Hospital of Valencia, Valencia, Spain; 26General University Hospital in Prague, Prague, Czech Republic; 27National Cancer Institute Regina Elena, IRCCS, Rome, Italy; 28Royal Marsden Hospital – London, London, UK; 29Heliópolis Sawicki Clinical Hospital at the Karol Marcinkowski Medical University, Poznan, Poland; 30University Hospital Innsbruck – Tyrolean Hospital, Innsbruck, Austria; 31Mersana Therapeutics, Cambridge, MA; 32Stephenson Cancer Centre-University of Oklahoma, Oklahoma City, OK

10.1136/ijgc-2022-ESGO.511

**Introduction/Background** UpRi is a first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that enables high drug-to-antibody ratio and controlled bystander effect. NaPi2b is a sodium-dependent phosphate transporter protein broadly expressed in high-grade serous epithelial ovarian, fallopian tube and primary peritoneal cancers (HGSC), with limited expression in healthy tissues. Preliminary antitumor activity from the Phase 1b expansion cohort of heavily pretreated patients with recurrent HGSC has been reported (Richardson et al., SGO 2022). These data suggested clinically meaningful activity in patients, notably in those with NaPi2b-high tumors (TPS ≥75). Effective and well-tolerated treatments for platinum-resistant ovarian cancer (PROC) remain a substantial unmet medical need. The standard of care, single agent chemotherapy, has limited efficacy, significant toxicities, and short duration of response. UPLIFT was designed as a single-arm Ph2 registrational trial for UpRi monotherapy in PROC.

**Methodology** UPLIFT is enrolling patients with platinum-resistant HGSC with up to 4 prior lines of therapy (LoT). Prior bevacizumab is required for patients with 1–2 prior LoT only; it is not required for patients with 3–4 prior LoT. Patients may enroll regardless of NaPi2b expression; ≤ Grade 2 peripheral neuropathy is permitted. Primary platinum refractory patients are excluded. UPLIFT will enroll ~180 patients globally, including approximately 100 patients with NaPi2b-high expression. UpRi will be dosed intravenously at 36 mg/m² up to ~80 mg dose maximum every 4 weeks. Baseline tumor samples (fresh or archived) will be collected for central analysis of NaPi2b expression. Based on data from the Ph1b expansion cohort, the cut-off for high NaPi2b expression is Tumor Proportion Score (TPS) ≥75. The primary endpoint is ORR in NaPi2b-high expressing patients. Secondary endpoints include ORR in the overall population, duration of response, and safety. UPLIFT is being conducted in collaboration with ENGOT (ENGOT-ow67) and GOG (GOG-3048). NCT03319628

**Results** N/A trial in progress

**Conclusion** N/A trial in progress

**2022-RA-464-ESGO**

**A PHASE I DOSE ESCALATION AND EXPANSION COHORT TRIAL OF CARBOPLATIN AND GEMCITABINE WITH THE ATR INHIBITOR BERZOSERTIB IN FIRST OR SECOND RECURRENCE PLATINUM SENSITIVE EPITHELIAL OVARIAN, PERITONEAL, AND FALLOPIAN TUBE CANCER**

1Andrea E Wahner Hendrickson, 2Nathan Foster, 3Bradley R Corr, 4Linda Duska, 5Merry J Markham, 6Kristina Butler, 7Eugenia Girda, 8Rachel Ware Miller, 9Katherine Ameson, 10Katherine Gano, 11Janelle Johnson, 12Geoffrey Shapiro, 13Larry Rubinstein, 14S Percy Ivy, 15Eise Kohn, 16Alex Adjei, 17Scott Kaufmann. 1Mayo Clinic, Rochester, MN; 2University of Colorado, Anschutz Medical Center, Aurora, CO; 3University of Virginia School of Medicine, Charlottesville, VA; 4Division of Hematology and Oncology, University of Florida, Gainesville, FL; 5Mayo Clinic, Scottsdale, AZ; 6Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; 7University of Kentucky Markey Cancer Center, Lexington, KY; 8Mayo Clinic, Rochester, MN; 9Dana-Farber Cancer Institute, Boston, MA; 10Mayo Clinic, Scottsdale, AZ; 11National Cancer Institute, Bethesda, MD

10.1136/ijgc-2022-ESGO.512

**Introduction/Background** The combination of carboplatin and gemcitabine is a commonly used regimen for platinum-sensitive recurrent ovarian cancer. Preclinical studies showed that ATR knockdown in ovarian cancer cell lines sensitized to a wide variety of genotoxic stresses, including gemcitabine and cisplatin. A phase II study evaluating the addition of berzosertib to gemcitabine in platinum resistant ovarian cancer revealed an improvement in progression-free survival (PFS). We sought to assess the safety and preliminary efficacy signal of the triple combination therapy in high grade ovarian cancer (NCT02627443).

**Methodology** Eligible participants included women with histologically confirmed high grade serous or endometrioid epithelial ovarian, fallopian tube or peritoneal cancer in first or second platinum sensitive recurrence. Using a standard 3+3 design, participants were treated with carboplatin on day 1, gemcitabine on days 1 and 8, and escalating doses of berzosertib on days 2 and 9 of a 21 day cycle. An additional 22 participants enrolled at maximum tolerated dose (MTD). Tumor biopsies were obtained at 3 different timepoints in the expansion cohort.

**Results** Thirty-three eligible participants were enrolled across 7 institutions in the US, with 28 eligible patients treated at the MTD (6 during dose escalation, 22 during dose expansion). The MTD was deemed to be carboplatin AUC 4, gemcitabine 640 mg/m² and berzosertib 90 mg/m²/day with grade 4 thrombocytopenia as the only DLT. A confirmed response was observed in 14/28 (50%) participants. Median progression free survival was estimated to be 15.1 months (95% CI, 9.8-NE). The most common adverse events were cytopenias (96% grade 3-4 hematologic adverse event). Translational correlates from the expansion cohort are underway.